AR120898A1 - Agente para tratar o prevenir neuromielitis óptica en fase aguda - Google Patents

Agente para tratar o prevenir neuromielitis óptica en fase aguda

Info

Publication number
AR120898A1
AR120898A1 ARP200103643A ARP200103643A AR120898A1 AR 120898 A1 AR120898 A1 AR 120898A1 AR P200103643 A ARP200103643 A AR P200103643A AR P200103643 A ARP200103643 A AR P200103643A AR 120898 A1 AR120898 A1 AR 120898A1
Authority
AR
Argentina
Prior art keywords
agent
neuromyelitis optica
treat
prevent acute
acute
Prior art date
Application number
ARP200103643A
Other languages
English (en)
Inventor
Toshihide Yamashita
Takahide Itokazu
Hirotoshi Kataoka
Takeshi Hirata
Shosuke Iwamoto
Atsushi Sasaki
Original Assignee
Univ Osaka
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Mitsubishi Tanabe Pharma Corp filed Critical Univ Osaka
Publication of AR120898A1 publication Critical patent/AR120898A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Un agente para tratar o prevenir la neuromielitis óptica en fase aguda, y los síntomas de dolor en una neuromielitis óptica, que comprende una sustancia inhibidora de RGMa.
ARP200103643A 2019-12-26 2020-12-23 Agente para tratar o prevenir neuromielitis óptica en fase aguda AR120898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019236661 2019-12-26

Publications (1)

Publication Number Publication Date
AR120898A1 true AR120898A1 (es) 2022-03-30

Family

ID=76574443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103643A AR120898A1 (es) 2019-12-26 2020-12-23 Agente para tratar o prevenir neuromielitis óptica en fase aguda

Country Status (6)

Country Link
EP (1) EP4082574A1 (es)
JP (1) JPWO2021132673A1 (es)
CN (1) CN114901313A (es)
AR (1) AR120898A1 (es)
TW (1) TW202136312A (es)
WO (1) WO2021132673A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
CA2559069A1 (en) 2004-03-11 2005-09-22 Bioclues, Inc. Axon regeneration promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
PT3290441T (pt) * 2015-04-28 2019-12-02 Mitsubishi Tanabe Pharma Corp Proteína de ligação a rgma e utilização da mesma

Also Published As

Publication number Publication date
JPWO2021132673A1 (es) 2021-07-01
WO2021132673A1 (ja) 2021-07-01
EP4082574A1 (en) 2022-11-02
TW202136312A (zh) 2021-10-01
CN114901313A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
BR112017015059A2 (pt) inibidor de proteassoma e uso
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112018012255A2 (pt) método para tratar câncer
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
CL2020002993A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)
ECSP20082339A (es) Moduladores de la expresión de apol1
CO2022011661A2 (es) Anticuerpos contra la integrina αvβ8 para su uso en el tratamiento de la enfermedad renal
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CO2019014592A2 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CO2020009731A2 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
AR120898A1 (es) Agente para tratar o prevenir neuromielitis óptica en fase aguda
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112022001063A2 (pt) Inibidores de ferroportina para o uso na prevenção e tratamento de lesões renais
AR103381A1 (es) Composición farmacéutica para el tratamiento de micosis
BR102018006534A8 (pt) Métodos para melhorar a atividade dos retinoides
CL2023000702A1 (es) Usos de inhibidores de masp-2 para tratar la enfermedad de células falciformes
AR119002A1 (es) Composiciones y métodos para el tratamiento de la hemocromatosis